Sanofi to sell 50% of Opella in $17 billion deal with CD&R, job guarantees for France included
Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at around 16 billion euros ($17 billion), or 14 times estimated core earnings (EBITDA) for 2024.
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...
Miracle cures are few and far between. The best one can hope for is partial relief. So it is with Sanofi’s consumer health split. The French pharma group’s sale of a majority 50 per cent stake in its ...
Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to ...
French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...
Global investment firm CD&R announced an open offer to buy a 26% stake in Sanofi Consumer Healthcare India for Rs 2,983 crore ...
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback